Morphic Therapeutic Ended First Quarter With $658.8M In Cash, Cash Equivalents, And Marketable Securities; Cash Runway Into Second Half Of 2027
Morphic Therapeutic Ended First Quarter With $658.8M In Cash, Cash Equivalents, And Marketable Securities; Cash Runway Into Second Half Of 2027
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.